medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2022-29-8-12medalphabet-2897Research ArticleСтатьиМесто альфакальцидола в лечении остеопороза и остеопоротических переломовPlace of alfacalcidol in treatment of osteoporosis and osteoporotic fractureshttps://orcid.org/0000-0003-4739-4302ТоропцоваН. В.ToroptsovaN. V.

Торопцова Наталья Владимировна - доктор медицинских наук, зав. лабораторией остеопороза.

Москва

Toroptsova Natalya V. - DM Sci (habil.), head of Osteoporosis Laboratory.

Moscow

torop@irramn.ruhttps://orcid.org/0000-0001-6759-8367НикитинскаяО. А.NikitinskayaO. A.

Никитинская Оксана Анатольевна - кандидат медицинских наук, старший научный сотрудник лаборатории остеопороза.

Москва

Nikitinskaya Oksana A. - PhD Med, senior researcher at Osteoporosis Laboratory.

Moscow

https://orcid.org/0000-0002-2809-0197ДобровольскаяО. В.DobrovolskayaO. V.

Добровольская Ольга Валерьевна - кандидат медицинских наук, научный сотрудник лаборатории остеопороза.

Москва

Dobrovolskaya Olga V. - PhD Med, researcher at Osteoporosis Laboratory.

Moscow

ФГБНУ Научно-исследовательский институт ревматологии имени В.А. НасоновойРоссияV. A. Nasonova Research Institute of RheumatologyRussian Federation202225122022029Ревматология в общей врачебной практике (2)812Copyright © Торопцова Н.В., Никитинская О.А., Добровольская О.В., 20222022Торопцова Н.В., Никитинская О.А., Добровольская О.В.Toroptsova N.V., Nikitinskaya O.A., Dobrovolskaya O.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/2897

Альфакальцидол показал эффективность и безопасность в терапии больных с остеопорозом (ОП) при проведении различных клинических исследований. В статье представлены данные исследований, проведенных в реальной клинической практике, с целью оценить востребованность альфакальцидола в терапии больных ОП и приверженность пациентов лечению. Проведено анкетирование врачей и пациентов с ОП и низкоэнергетическими переломами. Альфакальцидол назначался врачами в 27 % случаев, при этом в 19 % – в комбинированной терапии в сочетании с антирезорбтивными препаратами. Среди пациентов альфакальцидол принимали 25 % опрошенных лиц со средней длительностью заболевания 3 года. Приверженность лечению в течение года составила 38 %. В ходе наблюдения за больными после произошедшего низкоэнергетического перелома терапию альфакальцидолом получали 31 % пациентов, среди которых приверженность лечению в течение 36 месяцев составила для монотерапии 50 %, а для комбинированной – 21 %. Таким образом, опрос показал, что в реальной клинической практике альфакальцидол весьма широко используется как при ведении пациентов с ОП, так и после произошедших низкоэнергетических переломов.

Alfacalcidol has shown its efficacy and safety in the treatment of patients with osteoporosis (OP) during various clinical studies. The article presents data from a study conducted in real clinical practice in order to assess the relevance of alfacalcidol in the treatment of OP patients and the patients' adherence to treatment. A survey of doctors and patients with OP and low-energy fractures was conducted. Alfacalcidol was prescribed by doctors in 27 % of cases, while in 19 % – in combination with antiresorptive drugs. Among the interviewed patients with the average duration of OP 3 years, 25 % of the respondents took alfacalcidol. Adherence to treatment during the last year was 38 %. Follow-up of patients after a low-energy fracture showed that 31 % of them received alfacalcidol, among whom treatment adherence for 36 months was 50 % for monotherapy, and 21 % for combination therapy. Thus, the survey showed that in real clinical practice, alfacalcidol is widely used both in the management of patients with OP and after low-energy fractures.

альфакальцидолостеопорозлечение остеопорозаостеопоротический переломприверженность лечениюalfacalcidolosteoporosistreatment of osteoporosisosteoporotic fractureadherence to treatmentReferencesОтчет об аудите бремени остеопороза в восьми странах Евразийского региона. https://osteoporosis-russia.ru/wp-content/uploads/2022/02/audit_osteoporosis_raop.pdfReport on the audit of the burden of osteoporosis in eight countries of the Eurasian region. https://osteoporosis-russia.ru/wp-content/uploads/2022/02/audit_osteoporosis_raop.pdfСкрипникова И. А. Активные метаболиты витамина D в лечении остеопороза и профилактике переломов. Фарматека; 2015; 4 (15): 22–26.Skripnikova I. A. Active metabolites of vitamin D in the treatment of osteoporosis and the prevention of fractures. Farmateka; 2015; 4 (15): 22–26. (in Russ.)Белая Ж. Е., Белова К. Ю., Бирюкова Е. В., Дедов И. И., и др. Федеральные клинические рекомендации по диагностике, лечению и профилактике остеопороза. Остеопороз и остеопатии. 2021; 24 (2): 4–47. https://doi.org/10.14341/osteo12930Belaya Z. E., Belova K. Yu., Biryukova E. V., Dedov I. I., et al. Federal clinical guidelines for diagnosis, treatment and prevention of osteoporosis. Osteoporosis and Bone Diseases. 2021; 24 (2): 4–47. (in Russ.) https://doi.org/10.14341/osteo12930Nuti R., Bianchi G., Brandi M. L., et al. Superiority of alfacalcidol compared to vitamin D plus calcium in lumbar bone mineral density in postmenopausal osteoporosis. Rheumatol Int. 2006; 26 (5): 445–453. https://doi.org/10.1007/s00296–005–0073–4Nuti R., Bianchi G., Brandi M. L., et al. Superiority of alfacalcidol compared to vitamin D plus calcium in lumbar bone mineral density in postmenopausal osteoporosis. Rheumatol Int. 2006; 26 (5): 445–453. https://doi.org/10.1007/s00296–005–0073–4Ringe J. D., Farahmand P., Schacht E. Alfacalcidol in men with osteoporosis: a prospective, observational, 2-year trial on 214 patients. Rheumatol Int. 2013; 33 (3): 637–643. https://doi.org/10.1007/s00296–012–2429-xRinge J. D., Farahmand P., Schacht E. Alfacalcidol in men with osteoporosis: a prospective, observational, 2-year trial on 214 patients. Rheumatol Int. 2013; 33 (3): 637–643. https://doi.org/10.1007/s00296–012–2429-xRinge J. D., Dorst A., Faber H. et al. Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis. Rheumatol Int. 2004; 24 (2): 63–70. https://doi.org/10.1007/s00296–003–0361–9Ringe J. D., Dorst A., Faber H. et al. Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis. Rheumatol Int. 2004; 24 (2): 63–70. https://doi.org/10.1007/s00296–003–0361–9Ringe J. D., Faber H., Fahramand P., Schacht E. Alfacalcidol versus plain vitamin D in the treatment of glucocorticoid/inflammation-induced osteoporosis. J Rheumatol Suppl. 2005; 76: 33–40.Ringe J. D., Faber H., Fahramand P., Schacht E. Alfacalcidol versus plain vitamin D in the treatment of glucocorticoid/inflammation-induced osteoporosis. J Rheumatol Suppl. 2005; 76: 33–40.Richy F., Ethgen O., Bruyere O., Reginster J. Y. Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int. 2004; 15 (4): 301–310. https://doi.org/10.1007/s00198–003–1570–5Richy F., Ethgen O., Bruyere O., Reginster J. Y. Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int. 2004; 15 (4): 301–310. https://doi.org/10.1007/s00198–003–1570–5De Nijs R. N., Jacobs J. W., Algra A., et al. Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D 3 analogues: a review with metaanalysis of randomized controlled trials including organ transplantation studies. Osteoporos Int. 2004; 15 (8): 589–602. https://doi.org/10.1007/s00198–004–1614–5De Nijs R. N., Jacobs J. W., Algra A., et al. Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D 3 analogues: a review with metaanalysis of randomized controlled trials including organ transplantation studies. Osteoporos Int. 2004; 15 (8): 589–602. https://doi.org/10.1007/s00198–004–1614–5Deng J., Silver Z., Huang E., et al.The effect of calcium and vitamin D compounds on bone mineral density in patients undergoing glucocorticoid therapies: a network meta-analysis. Clin Rheumatol. 2021; 40 (2): 725–734. https://doi.org/10.1007/s10067–020–05294-yDeng J., Silver Z., Huang E., et al.The effect of calcium and vitamin D compounds on bone mineral density in patients undergoing glucocorticoid therapies: a network meta-analysis. Clin Rheumatol. 2021; 40 (2): 725–734. https://doi.org/10.1007/s10067–020–05294-yRinge J. D., Farahmand P., Schacht E., Rozehnal A. Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial). Rheumatol. Int. 2007; 27 (5): 425–434. https://doi.org/10.1007/s00296–006–0288-zRinge J. D., Farahmand P., Schacht E., Rozehnal A. Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial). Rheumatol. Int. 2007; 27 (5): 425–434. https://doi.org/10.1007/s00296–006–0288-zFelsenberg D., Bock O., Börst H. et al. Additive impact of alfacalcidol on bone mineral density and bone strength in alendronate treated postmenopausal women with reduced bone mass. J Musculoskelet Neuronal Interact. 2011; 11 (1): 34–45.Felsenberg D., Bock O., Börst H. et al. Additive impact of alfacalcidol on bone mineral density and bone strength in alendronate treated postmenopausal women with reduced bone mass. J Musculoskelet Neuronal Interact. 2011; 11 (1): 34–45.Ringe J. D., Schacht E. Natürliches vitamin D oder alfacalcidol als folgebehandlung langjähriger bisphosphonat-therapie bei postmenopausaler osteoporose. Osteologie. 2012; 21: 83–87.Ringe J. D., Schacht E. Natürliches vitamin D oder alfacalcidol als folgebehandlung langjähriger bisphosphonat-therapie bei postmenopausaler osteoporose. Osteologie. 2012; 21: 83–87.Tinetti M. E. Clinical practice. Preventing falls in elderly persons. N Engl J Med 2003 Jan 2; 348 (1): 42–9. https://doi.org/10.1056/NEJMcp020719Tinetti M. E. Clinical practice. Preventing falls in elderly persons. N Engl J Med 2003 Jan 2; 348 (1): 42–9. https://doi.org/10.1056/NEJMcp020719Richy F., Dukas L., Schacht E. Differential effects of D-hormone analogs and native vitamin D on the risk of falls: A comparative meta-analysis. Calcif Tissue Int. 2008; 82 (2): 102–107. doi: https://doi.org/10.1007/s00223–008–9102–0Richy F., Dukas L., Schacht E. Differential effects of D-hormone analogs and native vitamin D on the risk of falls: A comparative meta-analysis. Calcif Tissue Int. 2008; 82 (2): 102–107. doi: https://doi.org/10.1007/s00223–008–9102–0Bischoff-Ferrari H.A., Dawson-Hughes B., Staehelin H. B. et al. Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ. 2009; 339: b3692. https://doi.org/10.1136/bmj.b3692Bischoff-Ferrari H.A., Dawson-Hughes B., Staehelin H. B. et al. Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ. 2009; 339: b3692. https://doi.org/10.1136/bmj.b3692Ito S., Harada A., Kasai T., et al. Use of alfacalcidol in osteoporotic patients with low muscle mass might increase muscle mass: an investigation using a patient database. Geriatr Gerontol Int. 2014; 14 Suppl 1: 122–128. https://doi.org/10.1111/ggi.12222Ito S., Harada A., Kasai T., et al. Use of alfacalcidol in osteoporotic patients with low muscle mass might increase muscle mass: an investigation using a patient database. Geriatr Gerontol Int. 2014; 14 Suppl 1: 122–128. https://doi.org/10.1111/ggi.12222Scharla S. H., Schacht E., Bawey S. et al. Pleiotropic effect of alfacalcidol in elderly patients with rheumatoid arthritis. Arthr Rheum. 2003; 23: 268–274. https://doi.org/10.1007/s00393–006–0094–8Scharla S. H., Schacht E., Bawey S. et al. Pleiotropic effect of alfacalcidol in elderly patients with rheumatoid arthritis. Arthr Rheum. 2003; 23: 268–274. https://doi.org/10.1007/s00393–006–0094–8Orimo H. Clinical Application of 1α (OH) D 3 in Japan. Akt. Rheumatol. 1994; 19 Suppl: 27–30.Orimo H. Clinical Application of 1α (OH) D 3 in Japan. Akt. Rheumatol. 1994; 19 Suppl: 27–30.Dukas, L., Bischoff, H. A., Lindpaintner, et al. Alfacalcidol reduces the number fallers in a community-dwelling elderly population with a minimum calcium intake of more than 500 mg daily. J Am Geriatr Soc. 2004; 52: 230–236. https://doi.org/10.1111/j.1532–5415.2004.52060.xDukas, L., Bischoff, H. A., Lindpaintner, et al. Alfacalcidol reduces the number fallers in a community-dwelling elderly population with a minimum calcium intake of more than 500 mg daily. J Am Geriatr Soc. 2004; 52: 230–236. https://doi.org/10.1111/j.1532–5415.2004.52060.x

The authors declare that there are no conflicts of interest present.